You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

 

Online download statistics by month:

Online download statistics by month: January 2022 to March 2026

AbstractFullPdf
Jan 2022675693201
Feb 202221622966
Mar 202215315753
Apr 202217417845
May 202214114460
Jun 202221022851
Jul 202219920436
Aug 202222122637
Sep 202217217852
Oct 202219420371
Nov 202217317633
Dec 202215415337
Jan 202312612744
Feb 202314814943
Mar 202312913142
Apr 202313413949
May 202310811050
Jun 2023868620
Jul 202312012048
Aug 2023989837
Sep 2023868725
Oct 2023959548
Nov 202311111127
Dec 202314314430
Jan 2024666632
Feb 2024686826
Mar 202414414452
Apr 202411011129
May 2024969735
Jun 2024797844
Jul 202410911031
Aug 2024626233
Sep 2024525327
Oct 2024949943
Nov 2024969852
Dec 202412012240
Jan 2025727250
Feb 2025828247
Mar 2025727221
Apr 202511211337
May 2025888928
Jun 2025575725
Jul 2025220
Aug 2025110
Mar 2026110
Total564957631857